细胞免疫功能检测在乳腺癌临床分期及预后评估中的价值分析  

Value analysis of cellular immune function test in clinical staging and prognosis evaluation of breast cancer

作　　者：金妍[1] JIN Yan(Department of Clinical Laboratory,Shantou Central Hospital in Guangdong Province,Shantou 515031,China)

机构地区：[1]广东省汕头市中心医院检验科

出　　处：《中国现代医生》2019年第12期124-126,共3页China Modern Doctor

摘　　要：目的探讨细胞免疫功能检测在乳腺癌临床分期及预后评估中的应用价值。方法将2015年7月~2018年8月接收的80例女性乳腺癌患者作为观察组,另选取同时期乳腺正常的80例女性对象作为对照组,比较两组对象的外周血T淋巴细胞亚群免疫功能的检测结果。结果观察组患者CD3+均低于对照组,差异有统计学意义(P<0.05);乳腺癌Ⅲ、Ⅳ期患者CD8+明显高于Ⅰ、Ⅱ期患者及对照组,差异有统计学意义(P<0.05);乳腺癌Ⅲ、Ⅳ期患者CD3+、CD4+、CD4+/CD8+低于Ⅰ、Ⅱ期患者及对照组,差异有统计学意义(P<0.05)。结论细胞免疫功能检测在乳腺癌分期及预后评估中具有较好的应用价值,值得应用并推广。Objective To investigate the application value of cellular immune function test in clinical staging and prognosis evaluation of breast cancer. Methods 80 female breast cancer patients received from July 2015 to August 2018 were enrolled in the study. Another 80 female subjects with normal breasts were selected as the control group. The test results of immune function of the peripheral blood T lymphocyte subsets of the two groups were compared. Results The data showed that the CD3+ of breast cancer patients was lower than that of the control group, and the difference was statistically different(P<0.05). The CD8+ of patients with stage Ⅲ and Ⅳ breast cancer was significantly higher than that of patients with stage Ⅰ and Ⅱ and the control group. There were statistical differences between two data sets(P<0.05). CD3+, CD4+, CD4+/CD8+ in patients with stage Ⅲ and Ⅳ breast cancer was lower than that in stage Ⅰ and Ⅱ patients and the control group, and the data were statistically different(P<0.05). Conclusion The detection of cellular immune function has a good application value in the staging and prognosis evaluation of breast cancer, which is worthy of application and promotion.

关 键 词：乳腺癌 细胞免疫功能 T淋巴细胞亚群 临床分期 预后 

分 类 号：R473.71[医药卫生—护理学]